Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEIH.L Regulatory News (EIH)

  • There is currently no data for EIH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

29 Sep 2017 17:17

RNS Number : 3200S
EIH PLC
29 September 2017
 

29 September 2017

 

EIH PLC

("EIH" or the "Company")

 

Interim Results

The Company announces its interim results for the six months from 1 January 2017 to 30 June 2017. A copy of this announcement will shortly be available for inspection at www.eihplc.co.uk.

Chairman's Statement

The Company made a profit of US$0.6m for the six month period to 30 June 2017 (six month period to 30 June 2016: loss US$0.5m), and therefore earnings per share for the six month period to 30 June 2017 was 0.92 cents (six month period to 30 June 2016: loss per share 0.85 cents). The reason for the profit generated in the current period is due to the US$0.8m increase in fair value of the Company's investment in Evolvence India Fund PCC.

 

The unaudited net assets of the Company as at 30 June 2017 were valued at US$25.9m and therefore net asset value ("NAV") per share at that date was 40.2 cents based on 64,500,002 ordinary shares in issue (31 December 2016 NAV per share: 43.3 cents).

 

During the period under review, on 21 February 2017, the Company made a capital distribution of 4 cents per share to shareholders of the Company registered as at 17 February 2017, equivalent to approximately US$2.58m.

 

While the NAV per share decreased by 7.2% in the period under review, after adjusting for the capital distribution of 4.0 cents per share made in February 2017, the Company's NAV rose by 2.1% in the period.

 

The Company has separately announced today that it intends to make a further capital distribution of 1.5 cents per share to shareholders of the Company registered as at 20 October 2017, equivalent to approximately US$0.97m.

 

Total operating costs during the period were US$0.23m, or 1.3% below the comparable prior year figure. In addition, the Company paid certain annual management fees and expenses to Evolvence India Fund PCC ("EIF") in respect of its commitments. These costs are embedded in the capital account of EIF and do not appear in the Company's statement of comprehensive income.

 

The Company's investment portfolio comprises the following (based on unaudited values as at 30 June 2017):

 

Table 1. Investments

Capital Commitment

Capital Invested

Capital Distribution

Fair value Adjustment

Fair Value

US$'000

US$'000

US$'000

US$'000

US$'000

Fund Investments (equity)

Evolvence India Fund PCC

45,120

45,120

(26,970)

1,097

19,247

Direct Investments (equity)

EIF Co Invest VII (RSB Group)

 

6,970

 

6,970

 

(29)

 

(1,430)

 

5,511

52,090

52,090

(26,999)

(333)

24,758

Further details on the Company's investment portfolio are set out below and in Note 5 to the interim financial statements.

 

EIF

As at 30 June 2017 the Company had US$18.2m invested in EIF (capital called less refund capital contributions), equivalent to 28.1 cents per share. At the reporting date the Fair Value (unaudited) of the Company's investment in EIF was US$19.2m, equivalent to 29.8 cents per share, representing a 1.06 x multiple over cost. EIF is now fully drawn down.

In local currency terms, the S&P BSE SENSEX Indian stock market index advanced by 16.1% during the period in review. It is also noted that the Indian Rupee ("INR") strengthened by 5.1% in value against the US Dollar during the period in review.

Against this backdrop EIF's underlying private equity funds performed reasonably such that on the basis of beginning and end period values, and adjusting for drawdowns and distributions made during the period, the fair value of EIF's underlying funds increased by approximately 7.8% in US Dollar terms, while their value increased by approximately 2.6% in INR terms. On the same basis of measurement, the value of EIF's direct investments increased by approximately 1.0% in US Dollar terms, while in INR terms a decrease of approximately 3.9% was experienced.

EIF's private equity fund exposure is weighted towards funds with vintages of 2006 and later. The four funds of these vintages comprise 76.8% of EIF's private equity fund weighting. The remaining six funds, with a 23.2% weighting, are all 2004 and 2005 vintages. EIF's three largest funds constitute 73.0% of EIF's private equity fund weighting. These funds are Jacob Ballas India Fund III (Growth / PIPE category), JMF India Fund I (Growth category) and HI-REF International LLC (Real Estate category). The majority of EIF's ten underlying private equity funds have fully drawn down their committed capital from EIF, and EIF's remaining commitments are concentrated in one fund, HI-REF International LLC Fund. During the period under review, EIF received net distributions from all except three of its funds, while drawdowns were extremely limited.

The Directors have reviewed certain underlying financial information provided to us by EIF's Investment Manager and we remain confident that as EIF's underlying portfolio matures and further realisations are achieved, further cash distributions will be received by the Company.

EILSF Co-invest I / Gland Pharma Limited ("Gland")

At the beginning of the period under review and calculated on a "look through" basis, the Company retained an approximate US$2.0m interest in EILSF Co-invest I (held through EIF Co Invest X and EIF) representing its share of the Gland proceeds retained to address any potential contingencies. The final distribution amounting to US$1.4m comprising largely of the Company's share of its interest in EILSF Co-invest I occurred in January 2017.

RSB Group ("RSB")

RSB is a large automotive components group based in Pune with a multi-product portfolio comprising of propeller shafts, gears, axles, machined engine components, trailers and construction equipment parts. The Company's direct investment in RSB is held through EIF Co Invest VII. The shareholders in EIF Co Invest VII are the Company and EIF, which invested US$7.0m and US$10.0m respectively, for a total investment of US$17.0m. No fees are payable on the Company's investment in EIF Co Invest VII, while the Company's indirect investment in RSB (through its interest in EIF) attracts standard management and carried interest fee arrangements. Through the above arrangements, and on a look-through basis, the Company has a total of US$6.9m invested in RSB (at cost) compared to the US$7.0m invested in RSB through EIF Co Invest VII.

Through the above arrangements, and on a look-through basis, the fair value of the Company's total interest in RSB is 10.7 cents per share; while the fair value of the Company's direct interest in RSB (held through EIF Co Invest VII) is 8.5 cents per share. These values represent a 0.8 times multiple over cost. The Fair Value of the Company's interest in RSB is based on a valuation performed by EIF's investment manager.

Table 2. Investments (Fair Values)

As per LP reports

RSB

(EIF)

Pro-forma

 

US$'000

US$'000

US$'000

Fund Investments

 

 

 

EIF (PE funds)

11,730

 

11,730

EIF (direct investments)

7,065

(1,424)

5,641

EIF (other)

452

 

452

Direct Investments

 

 

 

RSB Group

5,511

1,424

6,935

 

24,758

-

24,758

 

Table 2 extracts the Company's "look through" interest in RSB (from EIF) and adds it to the Company's direct interest in RSB (held by EIF Co Invest VII). On this basis, 28.0% of the Company's Financial Assets at Fair Value (US$6.9m, equivalent to 10.7 cents per share), is accounted for by its interest in RSB on an underlying pro-forma basis.

Table 2 further shows that 47.4% of the Company's Financial Assets at Fair Value is accounted for by its interests in EIF's ten PE fund investments, and a further 22.8% by its interests in EIF's direct investments (excluding RSB).

Board changes

On 26 June 2017, Paul Garnett resigned, and Brett Miller was appointed, a director of the Company. On 30 June 2017, Andrew Baker resigned, and Tim Shepherd was appointed, the secretary of the Company.

Other matters

At the date of signing this report, the Company holds US$1.12m in net cash balances, equivalent to 1.74 cents per share.

As a Board we will continue to manage operating costs carefully. Our objective remains to realise assets at the appropriate time and value, and to return the proceeds, less expenses, to our shareholders.

On behalf of the Board of Directors, I thank all Shareholders for their support.

Respectfully yours,

 

Rhys Cathan Davies

29 September 2017

For further information, please contact:

 

EIH PLC

Rhys Davies

Tel: +41 (0) 79 620 0215

 

 

Nplus1 Singer Advisory LLP (Nominated Adviser)

James Maxwell / Alex Laughton-Scott

+44 (0)20 7496 3000

 

 

 

 

 

 

 

 

EIH PLC

UNAUDITED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2017

For the period from 1 January

2017 to

 30 June 2017

 

For the period from 1 January

2016 to

 30 June 2016

 

 Note

US$'000

US$'000

Income

 Interest income on cash balances

 

 

1

 

1

 

 

Loss on disposal of investments at fair value through profit or loss

 

 

(4)

 

-

Fair value movement on investments at fair value through profit or loss

 

 

 

824

 

(318)

Net investment income/(expenditure)

821

(317)

Expenses

Administrative expenses

(103)

(107)

Legal and other professional fees

(100)

(98)

Audit fees

(22)

(20)

Other expenses/income

(2)

(5)

Total operating expenses

(227)

(230)

Profit/(loss) before taxation for the period

594

(547)

Income tax expense

-

-

Profit/(loss) after taxation for the period

594

(547)

Other comprehensive income

-

-

Total comprehensive income/(expenditure) for the period

 

594

 

(547)

Basic and fully diluted earnings/(loss) per share (US cents)

 

6

 

0.92

 

(0.85)

 

The accompanying notes form an integral part of these interim financial statements.

 

 

 

 

 

 

 

 

EIH PLC

UNAUDITED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2017

 

As at 30 June

2017

As at 31 December 2016

Note 

US$'000

US$'000

Non-current assets

Financial assets at fair value through profit or loss

 

 

24,758

 

26,645

Total non-current assets

24,758

26,645

Current assets

Trade and other receivables

37

18

Cash and cash equivalents

1,208

1,314

Total current assets

1,245

1,332

Total assets

26,003

27,977

Equity

Issued share capital

1,265

1,265

Share premium

22,402

24,982

Retained earnings

2,261

1,667

Total equity

25,928

27,914

Current liabilities

Trade and other payables

75

63

Total current liabilities

75

63

Total liabilities

75

63

Total equity and liabilities

26,003

27,977

 

The accompanying notes form an integral part of these interim financial statements.EIH PLC

UNAUDITED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 JUNE 2017

 

Share capital

 

US$'000 

Share

premium

US$'000

Retained earnings

US$'000

Total

 

US$'000

Balance at 1 January 2016

1,265

26,595

4,063

31,923

Total comprehensive income

Loss for the period

-

-

(547)

(547)

 

Transactions with owners of the company recorded directly in equity

Return of capital

-

-

-

-

Balance at 30 June 2016

 1,265

26,595

3,516

31,376

 

Balance at 1 January 2017

 

1,265

 

24,982

 

1,667

 

27,914

Total comprehensive income

Profit for the period

-

-

594

594

Transactions with owners of the company recorded directly in equity

Return of capital

-

(2,580)

-

(2,580)

Balance at 30 June 2017

1,265

22,402

2,261

25,928

 

The accompanying notes form an integral part of these interim financial statements.EIH PLC

UNAUDITED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS TO 30 JUNE 2017

 

 

For the period from

 1 January 2017 to

30 June 2017

 

For the period from

 1 January 2016 to

30 June 2016

Note

US$'000

US$'000

Cash flows from operating activities

Profit/(loss) before taxation

594

(547)

Adjustments:

Loss on disposal of investments at fair value through profit or loss

4

-

Fair value movement on investments at fair value through profit or loss

 

5

(824)

318

Interest income on cash balances

(1)

(1)

Operating loss before working capital changes

(227)

(230)

Increase in trade and other receivables

(19)

(6)

Increase in trade and other payables

12

18

Net cash used in operations

(234)

(218)

Net cash used in operating activities

(234)

(218)

Cash flows from investing activities

Interest income on cash balances

1

1

Proceeds from disposal of investment

1,352

-

Capital distribution received

5

1,355

723

Net cash generated by investing activities

2,708

724

Cash flows from financing activities

Return of capital

(2,580)

-

Net cash used in financing activities

(2,580)

-

Net (decrease)/increase in cash and cash equivalents

(106)

506

Cash and cash equivalents at 1 January

1,314

2,114

Cash and cash equivalents at 30 June

1,208

2,620

 

The accompanying notes form an integral part of these interim financial statements.

Notes to the Unaudited Interim Results

For the six months ended 30 June 2017

1 The Company

EIH PLC (formerly Evolvence India Holdings plc) was incorporated and registered in the Isle of Man under the Isle of Man Companies Act 1931-2004 on 10 November 2006 as a public company with registration number 118297C. On 28 March 2011 the Company re-registered under the Isle of Man Companies Act 2006 with registration number 006738V.

Pursuant to a prospectus dated 19 March 2007 there was a placing of up to 65,000,000 Ordinary Shares of £0.01 each. The number of Ordinary Shares in issue immediately following the placing was 65,000,002. The shares of the Company were admitted to trading on the Alternative Investment Market of the London Stock Exchange ("AIM") following the close of the placing on 23 March 2007. The Company purchased 500,000 of its own shares for US$0.60 each on 30 September 2011.

The Company's agents perform all significant functions. Accordingly, the Company itself has no employees.

2 Duration

The Company currently does not have a fixed life but the Board considers it desirable that Shareholders should have the opportunity to review the future of the Company at appropriate intervals. Accordingly, at the annual general meeting of the Company in 2018 a resolution will be proposed that the Company ceases to continue as presently constituted. Shareholders holding at least fifty one per cent of the shares must vote in favour of this resolution for it to be passed. If the resolution is not passed, a similar resolution will be proposed at every third annual general meeting of the Company thereafter. If the resolution is passed, the Directors will be required, within 3 months of the resolution, to formulate proposals to be put to Shareholders to reorganise, unitise or reconstruct the Company or for the Company to be wound up.

3 Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below.

3.1 Basis of presentation

These interim financial statements have been prepared in accordance with International Financial Reporting Standard (IFRS) IAS 34: Interim Financial Reporting. They do not include all of the information required for full annual financial statements and should be read in conjunction with the financial statements of the Company for the year ended 31 December 2016. The interim financial statements are unaudited.

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended 31 December 2016.

 

Notes to the Unaudited Interim Results

For the six months ended 30 June 2017 (continued)

3.2 Investments at fair value through profit or loss

Investments are designated as financial assets at fair value through profit or loss. They are measured at fair value with gains and losses recognised through profit or loss.

The Company's investments at fair value through profit and loss comprise funds and co-investment vehicles, where fair value is estimated by the Directors to be the Company's share of net asset value per latest financial results reported by the underlying fund administrator.

3.3 Segment reporting

The Company has one segment focusing on maximising total returns through investing in an Indian private equity portfolio of investments. No additional disclosure is included in relation to segment reporting, as the Company's activities are limited to one business and geographic segment.

4 Net asset value per share

 

The unaudited net asset value per share as at 30 June 2017 is 40.2 cents per share based on 64,500,002 ordinary shares in issue as at that date (31 December 2016: 43.3 cents per share based on 64,500,002 ordinary shares).

5 Financial assets at fair value through profit or loss

 

The objective of the Company is to make indirect investments in Indian private equity funds and companies via Mauritian based investment funds and to also co-invest directly in certain portfolio companies of the underlying funds. As at 30 June 2017, the investment portfolio comprised the following assets:

Investments (Unlisted)

Capital Commitment

Capital Invested

Capital Distribution

Fair value Adjustment

Fair Value

US$'000

US$'000

US$'000

US$'000

US$'000

Fund Investments (equity)

Evolvence India Fund PCC

45,120

45,120

(26,970)

1,097

19,247

Direct Investments (equity)

EIF Co Invest VII (RSB Group)

 

6,970

 

6,970

 

(29)

 

(1,430)

 

5,511

52,090

52,090

(26,999)

(333)

24,758

 

 

 

 

 

Notes to the Unaudited Interim Results

 

For the six months ended 30 June 2017 (continued)

5 Financial assets at fair value through profit or loss (continued)

 

The fair value of the Company's investments has been estimated by the Directors with advice from Evolvence India Advisors Inc. The movement in investments during the period was as follows:

30 June 2017

US$'000

31 December 2016

US$'000

Fair value brought forward

26,645

29,922

Disposal of investments at fair value

(1,356)

-

Capital distributions

(1,355)

(1,356)

Movement in fair value

824

(1,921)

Fair value at period/year end

24,758

26,645

 

The outstanding capital commitments as at 30 June 2017 were US$nil (31 December 2016: US$nil).

Evolvence India Fund PCC (EIF)

 

Evolvence India Fund PCC, a Protected Cell Company formed under the laws of Mauritius having limited liability, is a private equity fund of funds with a co-investment pool, focusing primarily on investments in India. The fund size of EIF is US$250m, of which approximately two-thirds have been invested in different private equity funds (including growth capital, mezzanine and real estate funds) with significant focus on India, and the balance has been invested in co-investment opportunities, primarily in Indian companies or companies with significant operations in India. The fund investments of EIF include Baring India Private Equity Fund II, IDFC Private Equity Fund II, India Value Fund II (Formerly GW Capital), Leverage India Fund, New York Life Investment Management India Fund II, Ascent India Fund, JM Financial India Fund I, HI-REF International LLC Fund, NYLIM Jacob Ballas India Fund III and IDFC Private Equity Fund III.

Valuation basis

The fair value of the investment in EIF is based on the Company's share of the net assets of EIF at 30 June 2017 per its results as reported by the underlying fund administrator. The financial statements of EIF are prepared under IFRS, with all investments stated at fair value. The valuation of the investment portfolio of EIF has been performed by its investment manager at 30 June 2017. The investment portfolio comprises investments in private equity funds, where fair value is based on reported net asset values, and co-investments in private companies where fair values are based on valuation techniques.

 

 

 

 

 

 

 

Notes to the Unaudited Interim Results

 

For the six months ended 30 June 2017 (continued)

5 Financial assets at fair value through profit or loss (continued)

 

EIF Co Invest VII

 

The Company has invested US$7m in RSB Group through a Special Purpose Vehicle (SPV), EIF Co Invest VII. RSB Group is a leading manufacturer of automotive components and construction aggregates. The fair value of the investment in Co Invest VII is based on the Company's share of the net assets of Co Invest VII at 30 June 2017 per its financial results as reported by the underlying fund administrator. The financial statements of EIF Co Invest VII are prepared under IFRS, with all investments stated at fair value. The underlying valuation of RSB Group, which is unlisted, is based on the trading multiples of RSB's comparable group and the application of a liquidity discount thereto.

EIF Co Invest X

 

The Company held its interest in Gland Pharma Limited through an SPV, EIF Co Invest X. EIF Co Invest X sold its interest in Gland Pharma Limited during the year ended 31 December 2014, but retained an amount of the sale proceeds to address any possible contingencies. The Company received its final distribution of US$1.4m in respect of this interest on 24 January 2017.

6 Earnings/(loss) per share

 

Basic and fully diluted earnings/(loss) per share is calculated by dividing the profit/(loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period:

 

30 June 2017

'000

30 June 2016

'000

Profit/(loss) attributable to equity holders of the Company (US$)

594

(547)

Weighted average number of ordinary shares in issue

64,500

64,500

Basic earnings/(loss) per share (cents per share)

0.92

(0.85)

 

There are no dilutive potential ordinary shares in issue, therefore there is no difference between the basic and fully diluted earnings per share for the period.

 

7 Subsequent events

 

The Company intends to make a further capital distribution of 1.5 cents per share to shareholders of the Company registered as at 20 October 2017, equivalent to approximately US$0.97m.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR SEIFMUFWSEFU
Date   Source Headline
7th May 202011:49 amRNSResult of EGM and Notice of Cancellation
7th Apr 20207:00 amRNSProposed AIM Cancellation and Notice of EGM
2nd Apr 20205:38 pmRNSReturn of Capital and COVID-19 Update
6th Dec 20197:00 amRNSReturn of Capital
29th Nov 20197:00 amRNSDelisting Update
21st Nov 20197:00 amRNSMarket Update
30th Sep 20194:30 pmRNSInterim Results
30th Jul 201911:15 amRNSResult of AGM
28th Jun 20197:00 amRNSPosting of 2018 Annual Results and Notice of AGM
24th May 20195:53 pmRNSHolding(s) in Company
1st May 20197:00 amRNSReturn of Capital
4th Apr 20195:00 pmRNSSale of RSB and Return of Capital
25th Jan 20197:00 amRNSHolding(s) in Company
21st Jan 20196:13 pmRNSHolding(s) in Company
18th Jan 201911:37 amRNSHolding(s) in Company
28th Sep 20187:00 amRNSInterim Results
26th Jul 201811:05 amRNSResult of AGM
28th Jun 20187:00 amRNSPosting of 2017 Annual Report and Notice of AGM
28th Jun 20187:00 amRNSReturn of Capital
20th Mar 20181:00 pmRNSReplacement: Return of Capital
20th Mar 20187:00 amRNSReturn of Capital
29th Sep 20175:17 pmRNSHalf-year Report
29th Sep 20175:13 pmRNSReturn of capital
24th Jul 201710:54 amRNSResults of Annual General Meeting
26th Jun 20176:01 pmRNSDirectorate Change
26th Jun 20176:00 pmRNSPosting of 2016 Annual Report and Notice of AGM
9th Feb 20178:05 amRNSReturn of Capital
26th Jan 20175:08 pmRNSHolding(s) in Company
25th Jan 20179:30 amRNSHolding(s) in Company
5th Jan 20177:00 amRNSUpdate re EIF
30th Sep 20167:00 amRNSHalf-year Report
25th Jul 20161:24 pmRNSResult of AGM
27th Jun 20165:37 pmRNSPosting of Annual Report & Notice of AGM
27th Jun 20167:00 amRNSFinal Results
27th Jun 20167:00 amRNSReturn of Capital
30th Nov 20155:57 pmRNSHolding(s) in Company
30th Sep 20157:00 amRNSInterim Results
30th Jun 201511:53 amRNSResult of AGM
9th Jun 20154:00 pmRNSNotice of AGM
5th Jun 20154:35 pmRNSFinal Results
30th Sep 20147:00 amRNSHalf Yearly Report
14th Jul 20143:19 pmRNSReturn of Capital
30th Jun 201411:57 amRNSResult of AGM
4th Jun 20147:00 amRNSNotice of AGM
3rd Jun 20147:00 amRNSFinal Results
3rd Dec 201311:16 amRNSHolding(s) in Company
2nd Dec 20134:09 pmRNSHolding(s) in Company
28th Nov 20135:14 pmRNSHolding(s) in Company
27th Nov 20133:14 pmRNSSale of Interest in Gland Pharma Limited
22nd Nov 20139:15 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.